Cargando…
Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009
BACKGROUND: To describe relevant pathological parameters of Danish male breast cancer patients (MBCP) diagnosed from 1980 to 2009, and to relate these data to treatment, overall survival (OS) and standardized mortality rate (SMR). MATERIALS AND METHODS: The MBCP cohort was defined from national Dani...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297815/ https://www.ncbi.nlm.nih.gov/pubmed/32108307 http://dx.doi.org/10.1007/s12282-020-01066-3 |
_version_ | 1783547087090089984 |
---|---|
author | Jylling, Anne Marie Bak Jensen, Vibeke Lelkaitis, Giedrius Christiansen, Peer Nielsen, Sarah Schulz Lautrup, Marianne Djernes |
author_facet | Jylling, Anne Marie Bak Jensen, Vibeke Lelkaitis, Giedrius Christiansen, Peer Nielsen, Sarah Schulz Lautrup, Marianne Djernes |
author_sort | Jylling, Anne Marie Bak |
collection | PubMed |
description | BACKGROUND: To describe relevant pathological parameters of Danish male breast cancer patients (MBCP) diagnosed from 1980 to 2009, and to relate these data to treatment, overall survival (OS) and standardized mortality rate (SMR). MATERIALS AND METHODS: The MBCP cohort was defined from national Danish registers. A total of 643 MBCP were identified with tissue available in 457. Among these, 384 were primary operable. Where tissue blocks were available, tumor type, grade, estrogen receptor (ER), progesteron receptor (PgR) and androgen-receptor (AR) status as well as HER 2 and Ki67 were performed. OS was quantified by Kaplan–Meier estimates and SMR was calculated based on mortality rate among patients relative to the mortality rate in the general population. RESULTS: Male breast cancer was more often of ductal type, grade II and a very high proportion were ER and AR positive and HER2 negative. Intrinsic subtypes based on immunohistochemical evaluation showed luminal subtype. Ki67 ratio increased over period of study. OS declined by increased age, bigger tumor size, positive lymph node status, higher grade and Luminal B subtype. Hazard ratio and relative risk of SMR were highest for patients aged < 60 years. CONCLUSION: Male breast cancer is of luminal subtype, but more often Luminal B. Ki67 is crucial in evaluation of subtypes by immunohistochemistry, but have limitations. Subtyping seems to be of major importance. AR also can have a role in future treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12282-020-01066-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7297815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-72978152020-06-19 Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009 Jylling, Anne Marie Bak Jensen, Vibeke Lelkaitis, Giedrius Christiansen, Peer Nielsen, Sarah Schulz Lautrup, Marianne Djernes Breast Cancer Original Article BACKGROUND: To describe relevant pathological parameters of Danish male breast cancer patients (MBCP) diagnosed from 1980 to 2009, and to relate these data to treatment, overall survival (OS) and standardized mortality rate (SMR). MATERIALS AND METHODS: The MBCP cohort was defined from national Danish registers. A total of 643 MBCP were identified with tissue available in 457. Among these, 384 were primary operable. Where tissue blocks were available, tumor type, grade, estrogen receptor (ER), progesteron receptor (PgR) and androgen-receptor (AR) status as well as HER 2 and Ki67 were performed. OS was quantified by Kaplan–Meier estimates and SMR was calculated based on mortality rate among patients relative to the mortality rate in the general population. RESULTS: Male breast cancer was more often of ductal type, grade II and a very high proportion were ER and AR positive and HER2 negative. Intrinsic subtypes based on immunohistochemical evaluation showed luminal subtype. Ki67 ratio increased over period of study. OS declined by increased age, bigger tumor size, positive lymph node status, higher grade and Luminal B subtype. Hazard ratio and relative risk of SMR were highest for patients aged < 60 years. CONCLUSION: Male breast cancer is of luminal subtype, but more often Luminal B. Ki67 is crucial in evaluation of subtypes by immunohistochemistry, but have limitations. Subtyping seems to be of major importance. AR also can have a role in future treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12282-020-01066-3) contains supplementary material, which is available to authorized users. Springer Japan 2020-02-27 2020 /pmc/articles/PMC7297815/ /pubmed/32108307 http://dx.doi.org/10.1007/s12282-020-01066-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Article Jylling, Anne Marie Bak Jensen, Vibeke Lelkaitis, Giedrius Christiansen, Peer Nielsen, Sarah Schulz Lautrup, Marianne Djernes Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009 |
title | Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009 |
title_full | Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009 |
title_fullStr | Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009 |
title_full_unstemmed | Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009 |
title_short | Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009 |
title_sort | male breast cancer: clinicopathological characterization of a national danish cohort 1980–2009 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297815/ https://www.ncbi.nlm.nih.gov/pubmed/32108307 http://dx.doi.org/10.1007/s12282-020-01066-3 |
work_keys_str_mv | AT jyllingannemariebak malebreastcancerclinicopathologicalcharacterizationofanationaldanishcohort19802009 AT jensenvibeke malebreastcancerclinicopathologicalcharacterizationofanationaldanishcohort19802009 AT lelkaitisgiedrius malebreastcancerclinicopathologicalcharacterizationofanationaldanishcohort19802009 AT christiansenpeer malebreastcancerclinicopathologicalcharacterizationofanationaldanishcohort19802009 AT nielsensarahschulz malebreastcancerclinicopathologicalcharacterizationofanationaldanishcohort19802009 AT lautrupmariannedjernes malebreastcancerclinicopathologicalcharacterizationofanationaldanishcohort19802009 |